NCT06350838View on ClinicalTrials.gov

Clinical Study to Investigate the Safety and Tolerance of Therapeutic BCG in Postoperative Adjuvant Therapy in Subjects With Moderate to High-risk Non-muscular Invasive Bladder Cancer (NMIBC)

PHASE1CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

November 11, 2022

Primary Completion Date

February 13, 2023

Study Completion Date

February 13, 2023

Conditions
Non-muscular Invasive Bladder Cancer
Interventions
DRUG

BCG for Therapeutic Use

Take 120 mg BCG for treatment, dissolved in 40 \~ 50 mL normal saline, bladder perfusion through catheter. The injection was performed once a week for 6 consecutive times.

Trial Locations (1)

415000

Hunan Cancer Hospital, Changsha

All Listed Sponsors
collaborator

Hunan Cancer Hospital

OTHER

lead

Chengdu CoenBiotech Co., Ltd

INDUSTRY